The approval by the FDA was based on a comprehensive submission, which included results from a usability study demonstrating that individuals over 18 years of age could self-administer or administer FluMist to eligible individuals 2-49 years of age.   

“The approval of FluMist for self-administration is an important step forward in making vaccines more accessible to fight the high annual burden of influenza. For more than 20 years, FluMist has been the only nasal spray flu vaccine licensed in the US and now it is also the only vaccine to help individuals, families and communities access an influenza vaccine conveniently through self- and caregiver administration outside of traditional healthcare settings,” says Iskra Reic, Executive Vice President, Vaccines and Immune Therapies, AstraZeneca.

Once available, individuals 18 and older will be able to have FluMist delivered directly to their homes via FluMist Home. FluMist Home will utilize an online pharmacy where eligible individuals complete a questionnaire that is reviewed by a pharmacist prior to receiving their vaccine for shipment. FluMist will continue to be available in offices and pharmacies for administration by healthcare professionals.